Today's Breaking News
- ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference
- FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation
- Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Latest R&D and Business News
- Aslan Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting atopic dermatitis
- Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline
- AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies
- pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology
- OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
- Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies
- Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
- Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
- Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
- CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics
- New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive Phase 1 results for the treatment of IBD in data presented at UEG Week Barcelona 2019
- Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board